Abstract:BTG1 (B-cell translocation gene 1) may inhibit proliferation and cell cycle progression, induce differentiation, apoptosis, and anti-inflammatory activity. The goal of this study was to clarify the clinicopathological and prognostic significances of BTG1 mRNA expression and related signal pathways in cancers. Using the Oncomine, TCGA (the cancer genome atlas), xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal), and Kaplan-Meier plotter databases, we undertook a bioinformatics study of BTG1 mRNA expression in cancers. BTG1 expression was lower in gastric, lung, breast and ovarian cancer than normal tissue due to its promoter methylation, which was the opposite to BTG1 expression. BTG1 expression was positively correlated with dedifferentiation and histological grading of gastric cancer (p < 0.05), with squamous subtype and young age of lung cancer (p < 0.05), with infrequent lymph node metastasis, low TNM staging, young age, white race, infiltrative lobular subtype, Her2 negativity, favorable molecular subtyping, and no postmenopause status of breast cancer (p < 0.05), and with elder age, venous invasion, lymphatic invasion, and clinicopathological staging of ovarian cancer (p < 0.05). BTG1 expression was negatively correlated with favorable prognosis of gastric, lung or ovarian cancer patients, but the converse was true for breast cancer (p < 0.05). KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis showed that the top signal pathways included cytokine-cytokine receptor interaction, cell adhesion molecules, chemokine, immune cell receptor and NF (nuclear factor)-κB signal pathways in gastric and breast cancer. The top hub genes mainly contained CD (cluster of differentiation) antigens in gastric cancer, FGF (fibroblast growth factor)-FGFR (FGF receptor) in lung cancer, NADH (nicotinamide adenine dinucleotide): ubiquinone oxidoreductase in breast cancer, and ribosomal proteins in ovarian cancer. BTG1 expression might be employed as a potential marker to indicate carcinogenesis and subsequent progression, even prognosis.

The effect of BTG1 expression on proliferation, apoptosis and invasion of non-small cell lung cancer cells

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial–Mesenchymal Transition

Epigenetic Downregulated ITGBL1 Promotes Non-Small Cell Lung Cancer Cell Invasion Through Wnt/PCP Signaling

Expression of BTG1 in HK-2 and 786-O and Its Influence on Cell Cycle and Apoptosis of HK-2 and 786-O

Effect of integrin β1 up-regulation on the migration and adhesion capacity of lung cancer cell

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

Effect of NUP88 gene on proliferation and invasion biological behavior of breast cancer cell line BT-20

Btg1 Inhibits Breast Cancer Cell Growth Through Induction Of Cell Cycle Arrest And Apoptosis

Btg1 Expression Correlates With The Pathogenesis And Progression Of Ovarian Carcinomas

Influences of Over-Expression of VEGF-C and Its Inhibition on Biological Characteristics of NCI-H446 Human Small-Cell Lung Cancer Cells

Expression of BTG1 in Renal Clear Cell Carcinoma and Its Role in 786-O Cell Proliferation and Apoptosis in Vitro

Regulation of BTG3 by Microrna-20B-5p in Non-Small Cell Lung Cancer.

BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.

Upregulation of BTG1 Enhances the Radiation Sensitivity of Human Breast Cancer in Vitro and in Vivo

MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer.

MiR-106 b Regulates Proliferation and Apoptosis of Non-small Cell Lung Cancer by Targeting BTG3

GTPBP2 positively regulates the invasion, migration and proliferation of non-small cell lung cancer

Interfering with ITGB1-DT expression delays cancer progression and promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway

BTG2 Inhibits the Proliferation, Invasion, and Apoptosis of MDA-MB-231 Triple-Negative Breast Cancer Cells